PURPOSE: Consensus guidelines for preventing chemotherapy-induced nausea and vomiting (CINV) are variably implemented in practice. The purpose of this study was to evaluate the impact of guideline-consistent/guideline-inconsistent CINV prophylaxis (GCCP/GICP) on the incidence of no CINV after cycle 1 of highly or moderately emetogenic chemotherapy (HEC or MEC). PATIENTS AND METHODS: This prospective observational study enrolled chemotherapy-naive adult outpatients who received single-day HEC or MEC at four oncology practice networks, all using electronic health record (EHR) systems, in Georgia, Tennessee, and Florida. Results from the Multinational Association of Supportive Care in Cancer Antiemesis Tool, a validated tool to measure CINV, administered 5 to 8 days postchemotherapy, were merged with EHR data. The primary end point, no CINV, defined as no emesis and no clinically significant nausea (score < 3 on 0-10 scale), was compared between cohorts using logistic regression. RESULTS: A total of 1,295 patients were enrolled (mean age, 59.3 years; 70.0% female; 35.5% HEC). The overall prevalence of GCCP was 57.3%. When corticosteroids were prescribed on days 2 to 4 after all HEC, GCCP for HEC increased from 28.7% to 89.8%; when NK1-receptor antagonists were prescribed after all MEC, GCCP for MEC increased from 73.1% to 97.8%. Over 5 days postchemotherapy, the incidence of no CINV was significantly higher in the GCCP cohort than the GICP cohort (53.4% v 43.8%; P < .001). The adjusted odds of no CINV with GCCP was 1.31 (95% CI, 1.07 to 1.69; P = .037). CONCLUSION: Increased adherence to antiemetic guidelines could significantly reduce the incidence of CINV after HEC and MEC.
PURPOSE: Consensus guidelines for preventing chemotherapy-induced nausea and vomiting (CINV) are variably implemented in practice. The purpose of this study was to evaluate the impact of guideline-consistent/guideline-inconsistent CINV prophylaxis (GCCP/GICP) on the incidence of no CINV after cycle 1 of highly or moderately emetogenic chemotherapy (HEC or MEC). PATIENTS AND METHODS: This prospective observational study enrolled chemotherapy-naive adult outpatients who received single-day HEC or MEC at four oncology practice networks, all using electronic health record (EHR) systems, in Georgia, Tennessee, and Florida. Results from the Multinational Association of Supportive Care in Cancer Antiemesis Tool, a validated tool to measure CINV, administered 5 to 8 days postchemotherapy, were merged with EHR data. The primary end point, no CINV, defined as no emesis and no clinically significant nausea (score < 3 on 0-10 scale), was compared between cohorts using logistic regression. RESULTS: A total of 1,295 patients were enrolled (mean age, 59.3 years; 70.0% female; 35.5% HEC). The overall prevalence of GCCP was 57.3%. When corticosteroids were prescribed on days 2 to 4 after all HEC, GCCP for HEC increased from 28.7% to 89.8%; when NK1-receptor antagonists were prescribed after all MEC, GCCP for MEC increased from 73.1% to 97.8%. Over 5 days postchemotherapy, the incidence of no CINV was significantly higher in the GCCP cohort than the GICP cohort (53.4% v 43.8%; P < .001). The adjusted odds of no CINV with GCCP was 1.31 (95% CI, 1.07 to 1.69; P = .037). CONCLUSION: Increased adherence to antiemetic guidelines could significantly reduce the incidence of CINV after HEC and MEC.
Authors: Priya Patel; Sara R Lavoratore; Jacqueline Flank; Meaghan Kemp; Ashlee Vennettilli; Helen Vol; Tracey Taylor; Elyse Zelunka; Anne Marie Maloney; Paul C Nathan; L Lee Dupuis Journal: Support Care Cancer Date: 2019-06-08 Impact factor: 3.603
Authors: Ethan Basch; Claire Snyder; Kristen McNiff; Rebecca Brown; Suzanne Maddux; Mary Lou Smith; Thomas M Atkinson; Doris Howell; Anne Chiang; William Wood; Nathan Levitan; Albert W Wu; Monika Krzyzanowska Journal: J Oncol Pract Date: 2014-04-22 Impact factor: 3.840
Authors: Pascale Dielenseger; Sussanne Börjeson; Cheryl Vidall; Annie Young; Patrick Jahn Journal: Support Care Cancer Date: 2019-02-19 Impact factor: 3.603
Authors: Yasmeen Razvi; Stephanie Chan; Thomas McFarlane; Erin McKenzie; Pearl Zaki; Carlo DeAngelis; William Pidduck; Ahmad Bushehri; Edward Chow; Katarzyna Joanna Jerzak Journal: Support Care Cancer Date: 2018-10-03 Impact factor: 3.603
Authors: Hoon-Kyo Kim; RueyKuen Hsieh; Alexandre Chan; Shiying Yu; Baohui Han; Yunong Gao; Ana Baños; Xiaoyan Ying; Thomas A Burke; Dorothy M K Keefe Journal: Support Care Cancer Date: 2014-08-21 Impact factor: 3.603